New gene therapy platform uses the brain's own transport system to ta…

Researchers at University of Rochester have engineered AAV vectors that target glial cells and exploit the brain's glymphatic system for gene delivery, enabling widespread therapeutic distribution while avoiding peripheral organs. The platform addresses both blood-brain barrier penetration and cellular selectivity, opening new treatment routes for progressive MS, Huntington's disease, and white matter disorders. If you're building therapies for glial cell disorders, this vector now clears the biggest technical hurdle—getting drugs into the brain and to the right cells. Rochester's engineered AAV5 and glymphatic route become the standard platform; every company targeting progressive MS, white matter disease, or glia-driven neurodegeneration now has a proven delivery method to license or build around.